A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

276 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study will be to assess how effective Xilonix is in the treatment of patients with symptomatic colorectal cancer. By blocking a substance that helps tumours grow and spread, Xilonix therapy may not only slow tumour growth, but also may improve symptoms of muscle loss, fatigue, appetite loss, and pain in patients with colorectal cancer. The effectiveness of the therapy will be measured by assessing the change in these symptoms for patients treated with Xilonix versus those treated with placebo. Reversal of muscle loss will be assessed with a type of X-ray called a DEXA scanner. Improvement in pain, appetite loss, and fatigue will be measured with a questionnaire that is completed by patients enrolled on the trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

NCT00272051

Metastases Colorectal Neoplasms Colorectal Carcinoma

COMPLETED PHASE3

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107

Stage II Colorectal Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma

NCT00859469

Mesothelioma

COMPLETED PHASE2

Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan

NCT00496704

Colorectal Cancer

UNKNOWN PHASE1/PHASE2

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

NCT00305188

Metastases Colorectal Neoplasms Colorectal Carcinoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptomatic Colorectal Cancer Advanced Colorectal Cancer Colorectal Cancer With Cachexia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo administered intravenously every 2 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Xilonix

Xilonix administered intravenously every 2 weeks

Group Type ACTIVE_COMPARATOR

Xilonix

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xilonix

Intervention Type BIOLOGICAL

Placebo

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects with pathologically confirmed colorectal carcinoma that is metastatic or unresectable and which is refractory to standard therapy. To be considered refractory, a subject must have failed both an oxaliplatin (oxaliplatin may have been in the adjuvant setting) and an irinotecan based regimen.
2. Symptomatic Disease: One symptom from each domain (metabolic and functional) must be present.

* Evidence of metabolic dysfunction, defined as the presence of one or more of the following:
* Any degree (up to 20%) of unintentional total body weight loss in the previous 6 months
* Serum Interleukin 6 levels ≥10 pg/ml
* Evidence of reduced function or presence of cancer related symptoms as determined by EORTC QLQ-C30.
* Appetite reduction, with a score of \>10
* Presence of fatigue, with a score of \>10
* Presence of Pain, with a score of \>10
* Decreased Role, Emotional and Social function, with a score of \< 90.
3. Eastern Cooperative Oncology Group (ECOG) performance status 1 or 2.

Exclusion Criteria

1. Mechanical obstruction that would prevent adequate oral nutritional intake.
2. \>20% total body weight loss in the previous 6 months.
3. Serious uncontrolled medical disorder, or active infection, that would impair the ability of the patient to receive protocol therapy.
4. Uncontrolled or significant cardiovascular disease, including:

* A myocardial infarction within the past 6 months.
* Uncontrolled angina within the past 3 months.
* Congestive heart failure within the past 3 months, if defined as NYHC-II.
* Diagnosed or suspected congenital long QT syndrome.
* Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes).
* Any history of second or third degree heart block (may be eligible if currently have a pacemaker).
* Heart rate \< 50 beats per minute on pre-entry electrocardiogram.
* Uncontrolled hypertension (blood pressure \>150 mm Hg systolic and \>95 mm Hg diastolic).
5. Dementia or altered mental status that would prohibit the understanding or rendering of informed consent.
6. Subjects who have not recovered from the adverse effects of prior therapy at the time of enrollment to ≤ grade 1; excluding alopecia and grade 2 neuropathy.
7. Subjects who have received extensive prior radiation therapy to the bone marrow. Extensive radiation therapy is defined as treatment of more than one axial bony metastasis. However for subjects with rectal cancer pelvic irradiation, in addition to treatment of one axial bony metastasis, is acceptable.
8. Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).
9. Known hepatitis B surface antigen and/or hepatitis C antibody or known history of infection.
10. History of tuberculosis (latent or active) or positive Interferon-gamma release assay (IGRA).
11. Receipt of a live (attenuated) vaccine within 1 month prior to Randomization
12. Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition to Xilonix™ or any component of its formulations.
13. Women who are pregnant or breastfeeding.
14. WOCBP or men whose sexual partners are WOCBP who are unwilling or unable to use an acceptable method of contraception for at least 1 month prior to randomization, for the duration of the study, and for at least 3 months after the last dose of study medication.
15. History of progressive multifocal leukoencephalopathy or other demyelinating disease.
16. Subjects on immunosuppressive therapy, including transplant patients.
17. Subjects with known brain metastases. Subjects with symptoms of brain metastases during screening should undergo CT imaging prior to randomization.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No